ID
11711
Descrizione
This study will evaluate the use of a prasugrel 60 mg loading dose (LD) administered during percutaneous coronary intervention (PCI) with and without a prior LD of clopidogrel on platelet inhibition in patients presenting with acute coronary syndrome (ACS). Platelet inhibition following a prasugrel LD in clopidogrel pretreated patients' will be determined in a time-dependent manner for two different prasugrel loading doses (30 mg and 60 mg). Understanding the effects of this combination on platelet inhibition will provide guidance to physicians on the use of prasugrel in patients who have already been pretreated with clopidogrel. https://clinicaltrials.gov/ct2/show/NCT01115738
collegamento
https://clinicaltrials.gov/ct2/show/NCT01115738
Keywords
versioni (1)
- 28/07/15 28/07/15 -
Caricato su
28 luglio 2015
DOI
Per favore, per richiedere un accesso.
Licenza
Creative Commons BY 4.0
Commenti del modello :
Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.
Commenti del gruppo di articoli per :
Commenti dell'articolo per :
Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.
Eligibility Clopidogrel to Prasugrel Acute Coronary Syndrome NCT01115738
Eligibility Criteria
- StudyEvent: ODM
Descrizione
Exclusion Criteria
Descrizione
Have cardiogenic shock at the time of randomization
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0036980
Descrizione
Have refractory ventricular arrhythmias
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0085612
Descrizione
Have New York Heart Association (NYHA) Class IV congestive heart failure
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0018802
Descrizione
Have systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 100 mm Hg on more than 1 assessment at any time from participant presentation of ACS treatment to enrollment
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0871470
Descrizione
Have systolic blood pressure greater than 180 mm Hg, or diastolic blood pressure greater than 100 mm Hg on more than 1 assessment at any time from participant presentation of ACS treatment to enrollment
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0428883
Descrizione
Have received fibrin-specific fibrinolytic therapy less than 24 hours prior to randomization
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0040044
Descrizione
Have active internal bleeding or history of bleeding diathesis
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0019080
Descrizione
Have clinical findings associated with an increased risk of bleeding
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C3251812
Descrizione
Prior history of ischemic or hemorrhagic stroke
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0559159
Descrizione
Intracranial neoplasm
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C1527390
Descrizione
arteriovenous malformation
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0003857
Descrizione
aneurysm
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0002940
Descrizione
Prior history of transient ischemic attack (TIA)
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0455536
Descrizione
Have an International Normalized Ratio (INR) known to be greater than 1.5 at the time of evaluation
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0525032
Descrizione
Have a platelet count of less than 100,000 per cubic millimeter (mm^3) at the time of evaluation
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0032181
Descrizione
Have anemia [hemoglobin (Hgb) less than 10 grams per deciliter (g/dL)] at the time of evaluation
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0002871
Descrizione
Have received 1 or more doses of a thienopyridine or other adenosine diphosphate (ADP) receptor inhibitor within 10 days prior to screening
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C2936588
Descrizione
Have been administered glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitor within the past 7 days or planned use of a GPIIb/IIIa inhibitor during PCI
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C3640054
Descrizione
Are receiving or will receive oral anticoagulation or other antiplatelet therapy, other than aspirin (ASA), which cannot be safely discontinued for the duration of the study.
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0354604
Descrizione
Are receiving daily treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) or cyclooxygenase-2 (COX2) inhibitors that cannot be discontinued during the study
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0003211
Descrizione
Are women who are known to be pregnant
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0549206
Descrizione
Breastfeeding
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0006147
Descrizione
Have known severe hepatic dysfunction (that is, with cirrhosis or portal hypertension)
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0085605
Descrizione
Have a history of intolerance or allergy to aspirin or approved thienopyridines (ticlopidine, clopidogrel or prasugrel)
Tipo di dati
boolean
Alias
- UMLS CUI-1
- C0004058
Similar models
Eligibility Criteria
- StudyEvent: ODM